PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.83 Million CAD | 18.65% |
| 2022 | 3.23 Million CAD | 10.32% |
| 2021 | 2.92 Million CAD | -2.77% |
| 2020 | 3.01 Million CAD | -36.57% |
| 2019 | 4.74 Million CAD | 30.05% |
| 2018 | 3.65 Million CAD | 33.87% |
| 2017 | 2.72 Million CAD | 1973.57% |
| 2016 | 131.55 Thousand CAD | 711.67% |
| 2015 | 16.2 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.03 Million CAD | 5.2% |
| 2024 Q2 | 4.19 Million CAD | 4.05% |
| 2023 Q3 | 3.77 Million CAD | 5.23% |
| 2023 Q1 | 3.4 Million CAD | 5.37% |
| 2023 Q4 | 3.83 Million CAD | 1.5% |
| 2023 Q2 | 3.58 Million CAD | 5.42% |
| 2023 FY | 3.83 Million CAD | 18.65% |
| 2022 Q1 | 2.85 Million CAD | -2.54% |
| 2022 FY | 3.23 Million CAD | 10.32% |
| 2022 Q3 | 3.35 Million CAD | 12.84% |
| 2022 Q2 | 2.97 Million CAD | 4.17% |
| 2022 Q4 | 3.23 Million CAD | -3.7% |
| 2021 Q3 | 2.78 Million CAD | -0.17% |
| 2021 FY | 2.92 Million CAD | -2.77% |
| 2021 Q2 | 2.78 Million CAD | 7.0% |
| 2021 Q1 | 2.6 Million CAD | -13.58% |
| 2021 Q4 | 2.92 Million CAD | 5.33% |
| 2020 Q4 | 3.01 Million CAD | 2.24% |
| 2020 Q2 | 3.22 Million CAD | -32.55% |
| 2020 FY | 3.01 Million CAD | -36.57% |
| 2020 Q1 | 4.78 Million CAD | 0.69% |
| 2020 Q3 | 2.94 Million CAD | -8.64% |
| 2019 FY | 4.74 Million CAD | 30.05% |
| 2019 Q4 | 4.74 Million CAD | -3.8% |
| 2019 Q3 | 4.93 Million CAD | 2.92% |
| 2019 Q1 | 4.48 Million CAD | 22.83% |
| 2019 Q2 | 4.79 Million CAD | 6.94% |
| 2018 Q3 | 3.35 Million CAD | -11.43% |
| 2018 FY | 3.65 Million CAD | 33.87% |
| 2018 Q4 | 3.65 Million CAD | 8.8% |
| 2018 Q2 | 3.78 Million CAD | 3.92% |
| 2018 Q1 | 3.64 Million CAD | 33.68% |
| 2017 Q2 | 2.41 Million CAD | 7939.96% |
| 2017 Q4 | 2.72 Million CAD | 11.63% |
| 2017 FY | 2.72 Million CAD | 1973.57% |
| 2017 Q1 | 30 Thousand CAD | -77.2% |
| 2017 Q3 | 2.44 Million CAD | 1.32% |
| 2016 Q3 | - CAD | -100.0% |
| 2016 Q2 | 105.84 Thousand CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | 131.55 Thousand CAD | 711.67% |
| 2016 Q4 | 131.55 Thousand CAD | 0.0% |
| 2015 FY | 16.2 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 43.37 Million USD | 91.16% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 34.694% |
| CSL Limited | 12.18 Billion USD | 99.969% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 87.119% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -407.029% |
| BioStem Technologies, Inc. | 4.71 Million USD | 18.62% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 81.138% |
| Qrons Inc. | 351.84 Thousand USD | -989.727% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3029.936% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 91.584% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 70.5% |
| Skye Bioscience, Inc. | 4.61 Million USD | 16.924% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1136.83% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -14807.936% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.082% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -508.524% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 90.694% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 6.982% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -854.133% |
| SQZ Biotechnologies Company | 27.47 Million USD | 86.043% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -64.843% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -304.333% |
| Mesoblast Limited | 118.7 Million USD | 96.77% |
| Marizyme, Inc. | 18.71 Million USD | 79.516% |
| Genus plc | 233.1 Million USD | 98.355% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -30.842% |
| Pharming Group N.V. | 171.54 Million USD | 97.765% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -331.745% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -185.369% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -411.223% |
| ContraFect Corporation | 2.88 Million USD | -33.085% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2729.919% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -165.099% |
| IMV Inc. | 28.88 Million USD | 86.726% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 32.239% |
| MultiCell Technologies, Inc. | 202.58 USD | -1892570.55% |
| ONE Bio Corp. | 19.71 Million USD | 80.552% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 93.331% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -156.509% |
| Q BioMed Inc. | 4.1 Million USD | 6.711% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 88.417% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -212.137% |
| Biomind Labs Inc. | 735.54 Thousand USD | -421.272% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 94.332% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -26.7% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -965.906% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2609.318% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -69.775% |
| GB Sciences, Inc. | 1.75 Million USD | -117.936% |
| Alpha Cognition Inc. | 1.22 Million USD | -214.181% |
| HST Global, Inc. | 98.31 Thousand USD | -3799.726% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1441.562% |
| Halberd Corporation | 150 Thousand USD | -2456.115% |
| Enzolytics Inc. | 996.33 Thousand USD | -284.826% |
| Agentix Corp. | 50 Thousand USD | -7568.344% |
| Resverlogix Corp. | 6.49 Million USD | 40.931% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1400.114% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 80.829% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 45.79% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -41.55% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -37398.015% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1811.2% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -59.909% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1572.186% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2479.259% |
| Kadimastem Ltd | 891.22 Thousand USD | -330.213% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1432.553% |
| LadRx Corporation | 33.6 Thousand USD | -11309.189% |
| Cell Source, Inc. | 9.25 Million USD | 58.568% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -407.029% |
| NovAccess Global Inc. | 2.19 Million USD | -74.29% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -1578.878% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1717.358% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 23.055% |
| Mobile Lads Corp. | 484.28 Thousand USD | -691.72% |
| CytoDyn Inc. | 30.07 Million USD | 87.252% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 50.969% |
| SYBLEU INC | 477.5 Thousand USD | -702.968% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 19.03% |
| International Stem Cell Corporation | 4.17 Million USD | 8.229% |
| Bioxytran, Inc. | 1.92 Million USD | -99.178% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6043.227% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -75.807% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 53.894% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 55.339% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -146.495% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1330.661% |
| Neutra Corp. | 54.15 Thousand USD | -6979.866% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -109.518% |
| PureTech Health plc | 25.51 Million USD | 84.971% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -213.192% |
| IXICO plc | 472.02 Thousand USD | -712.285% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 75.265% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 93.842% |
| CSL Limited | 12.18 Billion USD | 99.969% |
| Cellectis S.A. | 92.77 Million USD | 95.867% |